Molecular & Systems Epidemiology Lab
Dr. Mohsen Ghanbari
Dr. Ghanbari is a medical doctor and molecular epidemiologist working as Associate Professor and Principal investigator at the Department of Epidemiology, Erasmus University Medical Center Rotterdam, in the Netherlands. He has a multidisciplinary background due to training and working in the clinic, epidemiology, and molecular biology. His research focuses on the identification of underlying mechanisms and novel biomarkers for complex age-related diseases (e.g. Alzheimer’s disease, fatty liver disease, and cardio-metabolic diseases) using population-level omics data. The multidisciplinary aspects of his research have allowed him to make a bridge between Epidemiology and several biology laboratories at Erasmus MC and other academic institutions (e.g. Imperial College London and the Harvard T.H. Chan School of Public Health). He is currently involved in several (inter)national consortia in his field (e.g. CHARGE, COMETS, X-omics, BBMRI-NL) and leading some multi-centre collaborative projects. In addition to research, he is a dedicated teacher in multiple courses offered by the Netherlands Institute for Health Sciences (NIHES) for MSc and PhD students. He also coordinates ‘omics’ data in the population-based Rotterdam Study cohort (~18000 individuals) and the family-based Erasmus Rucphen Family study (~3000 individuals).
Molecular & Systems Epi Group
Dr. Ghanbari and his team have so far discovered the potential role of numerous non-coding RNAs in molecular pathways underlying neurodegenerative, cardiovascular and metabolic diseases. Moreover, his team has shown the impact of lifestyle factors on epigenetic regulation of gene expression in many complex diseases. The multidisciplinary aspects of his research have allowed him to make a bridge between Epidemiology and several biology laboratories at Erasmus MC and other academic institutions (e.g. Imperial College London and the Harvard T.H. Chan School of Public Health). Dr. Ghanbari is currently involved in several (inter)national consortia in his field (e.g., CHARGE, COMETS, X-omics, BBMRI-NL) and leading some multi-centre collaborative projects.
Dr. Abbas Dehghan in ICL
Dr. Dehghan is a medical doctor and an epidemiologist. He studied Epidemiology at Netherlands Institute for Health Sciences (NIHES) and worked with the Rotterdam Study at the department of epidemiology, Erasmus MC in the Netherlands for more than 10 years. In 2016, he joined the Department of Epidemiology and Biostatistics at Imperial College London as a reader in cardiometabolic disorders. Dr Dehghan is working on the genetics of omics, in particular metabolomics, and applying Mendelian Randomisation (MR) approach to investigate causal determinants of complex traits and diseases including cardiometabolic disorders, dementia and cancers. He is a member of the steering committee of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium and has led or been involved in many genome-wide association (GWAS) studies. Since January 2020, he is also the director of postgraduate research at the school of public health, Imperial College London. (https://www.imperial.ac.uk/people/a.dehghan)
Dr Rima Mustafa in ICL
Rima is a research associate in the Molecular Epidemiology Group at the Department of Epidemiology and Biostatistics, at Imperial College London. She holds a medical degree from Gadjah Mada University, Indonesia, and MSc and PhD in Molecular Epidemiology from ICL. During her PhD, she was working on the role of microRNAs in complex disorders using extensive genetic, molecular, and clinical data in population-based cohorts, such as the Rotterdam Study and the UK Biobank. In particular, she was the main analyst of the genetic regulation, omics integration and disease association of microRNAs. (https://www.imperial.ac.uk/people/r.Mustafa)
Prof. Daniel Levy in FHS
Dr. Levy received a B.A. from the University of Pennsylvania in 1976 and an M.D. from Boston University School of Medicine in 1980. He then completed his residency in internal medicine at University Hospital, Boston and a research fellowship in cardiology at Brigham and Women’s Hospital and Harvard School of Public Health. He joined the NHLBI’s Framingham Heart Study in 1984 and became the Study’s fourth director in 1994. Dr. Levy is also jointly a professor of medicine at Boston University School of Medicine and holds an adjunct faculty appointment at Harvard Medical School. He has been the recipient of many awards for his research accomplishments including two NIH Director’s Awards and the American Heart Association’s Population Research Prize in 2009, the AHA’s highest recognition for research achievements in epidemiology. Dr. Levy is a fellow of the American College of Cardiology and American Heart Association, and he is also a member of the American Society of Hypertension and Heart Failure Society of America. Dr. Levy’s main areas of research interest include the epidemiology and genetics of cardiovascular disease, with a focus on coronary disease, hypertension, and heart failure. He aims to merge the robust clinical and longitudinal data available from the Framingham Heart Study with the latest advances in genomic sciences to gain insight into the complex relations between complex cardiovascular traits and the onset of heart disease. (https://irp.nih.gov/pi/daniel-levy)
Alborn vito
mos nostra pertrone
Dr. Ghanbari is a medical doctor and molecular epidemiologist. He currently works as Associate Professor and Principal investigator at Erasmus University Medical Center Rotterdam in the Netherlands, where he leads the Molecular & Systems Epidemiology research group. He has a multidisciplinary background due to training and working in the clinic, epidemiology and molecular biology. His research focuses on the identification of genetic determinants and novel biomarkers for complex diseases (e.g. Alzheimer’s disease, type 2 diabetes, fatty liver disease). In addition to research, he is a dedicated teacher in multiple courses offered by the Netherlands Institute for Health Sciences (NIHES) and coordinates ‘omics’ data in the population-based Rotterdam Study cohort and the Erasmus Rucphen Family study.
Follow US
on These Social Media or Websites